Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
Healthcare
$25.04 +3.46%
+$0.64 today
- Market cap
- $1.70B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
52W Low $8.91High $44.60
Volume 0.27M
Average 0.71M
Income Statement
Follow revenue through to earnings.
Revenue
$10.00M
FY 2025 · Annual
+100.0% YoYOperating Income
-$211.38M
FY 2025 · Annual
Net Income
-$377.74M
FY 2025 · Annual
Income Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 50M | 5M | 10M |
| Cost of Revenue | 61.69M | 0 | 139.14M | 0 |
| Gross Profit | (61.69M) | 50M | (134.14M) | 10M |
| Gross Margin | — | 100.0% | -2682.8% | 100.0% |
| Research & Development | 62.69M | 60.03M | 139.14M | 168.06M |
| Selling, General & Admin | 13.51M | 17.11M | 29.75M | 53.32M |
| Operating Expenses | 14.51M | 87.15M | 29.75M | 221.39M |
| Depreciation & Amortization | 78K | 113K | 137K | 56K |
| EBITDA | (75.12M) | (27.03M) | (156.42M) | (370.43M) |
| EBITDA Margin | — | -54.1% | -3128.4% | -3704.3% |
| Operating Income | (76.2M) | (37.15M) | (163.89M) | (211.39M) |
| Operating Margin | — | -74.3% | -3277.8% | -2113.8% |
| Interest Income | 0 | 0 | 0 | 12.15M |
| Interest Expense | 0 | 0 | 0 | 7.33M |
| Other Income / Expenses | (43.08M) | 324K | 7.33M | (166.43M) |
| Income Before Tax | (119.28M) | (36.82M) | (156.56M) | (377.82M) |
| Pre-Tax Margin | — | -73.6% | -3131.2% | -3778.2% |
| Income Tax Expense | 0 | 301K | 429K | (79K) |
| Net Income | (119.28M) | (37.12M) | (156.99M) | (377.74M) |
| Net Margin | — | -74.2% | -3139.8% | -3777.4% |
| EPS (Basic) | (3.11) | (0.97) | (3.76) | (8.44) |
| EPS (Diluted) | (3.11) | (0.97) | (3.76) | (8.44) |
| 38.32M | 38.32M | 41.79M | 44.73M | |
| 38.32M | 38.32M | 41.79M | 44.73M |
ZBIO Earnings Waterfall · TTM
NASDAQ:ZBIO · Revenue to Net Income
Key Ratios
EPS$-9.10
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.9
P/S Ratio0.0
Analysis
$0 of revenue converted into -$425.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-9.10, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 6, 2026 | |
| 424B5 | 424B5 filing | Nov 6, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 |
How much revenue does ZBIO generate?
Zenas BioPharma, Inc. (ZBIO) reported $10.00M of revenue in fiscal 2025.
Is ZBIO profitable?
Zenas BioPharma, Inc. (ZBIO) reported -$377.74M of net income, with a net margin of -3777.4%.
Continue the stock analysis
Jump to another research area for this company.